Schedule 13D ownership disclosure

AVENUE THERAPEUTICS, INC.

Common Stock, $0.0001 Par Value · CUSIP: 05360L403

Event date: 2025-03-31

Filing-level shares
328,746.00
Percent of class
10.3%
  • Fortress Biotech, Inc.Reported CIK 0001429260

    Shares: 328,746.00 · Class: 10.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-031241
Form type
SCHEDULE 13D/A
Filer
AVENUE THERAPEUTICS, INC.
CIK
CIK 1644963
Filed
Apr 02, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub